Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma

Molecular Cancer Research

Volumn 10, Issue 3, 2012, Pages 454-468

  Shimizu, Takatsune ^a,c   Ishikawa, Tomoki ^a,b   Iwai, Sayaka ^a   Ueki, Arisa ^a   Sugihara, Eiji ^a,c   Onishi, Nobuyuki ^a   Kuninaka, Shinji ^a   Miyamoto, Takeshi ^a   Toyama, Yoshiaki ^a   Ijiri, Hiroshi ^d   Mori, Hajime ^d   Matsuzaki, Yumi ^a   Yaguchi, Tomonori ^a   Nishio, Hiroshi ^a   Kawakami, Yutaka ^a   Ikeda, Yasuo ^a   Saya, Hideyuki ^a,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; STROMA CELL; TUMOR MICROENVIRONMENT;

ANIMALS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA INHIBITORY FACTOR; MICE; NEOPLASM INVASIVENESS; OSTEOGENESIS; OSTEOSARCOMA; PHOSPHORYLATION; RNA, MESSENGER;

MURINAE;

EID: 84863399778     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0347     Document Type: Article

References (50)

1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-90. (Pubitemid 34111386)
2. Clark JCM, Dass CR. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008;134: 281-97. (Pubitemid 351170066)
3. Fletcher CDM, Unni KK, Mertens F, editors. Osteogenic tumours: WHO classification tumours of soft tissue and bone. Lyon, France:IARC Press; 2002.
4. Gazdar AF, Kadoyama C, Venzon D, Park JG, Tsai CM, Linnoila RI, et al. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr 1992;13:191-6.
5. Silverberg SG. Histologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15. (Pubitemid 30010638)
6. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8. (Pubitemid 29289430)
7. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 1999;5:1587-94. (Pubitemid 29282968)
8. McAllister SS, Weinberg RA. Tumor-host interactions: a far-reaching relationship. J Clin Oncol 2010;28:4022-8.
9. Bissell MJ, Radisky D. Putting tumors in context. Nat Rev Cancer 2001;1:46-54.
10. DeWever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008;123:2229-38.
11. Seruga B, Zhang H, Bernatein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008;8:887-99.
12. Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, Mabuchi Y, et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010;29:5687-99.
13. Ijiri H, Coulibaly F, Nishimura G, Nakai D, Chiu E, Takenaka C, et al. Structure-based targeting of bioactive proteins into cypovirus polyhedra and application to immobilized cytokines for mammalian cell culture. Biomaterials 2009;30:4297-308.
14. Mori H, Shukunami C, Furuyama A, Notsu H, Nishizaki Y, Hiraki Y. Immobilization of bioactive fibroblast growth factor-2 into cubic proteinous microcrystals (bombyx mori cypovirus polyhedra) that are insoluble in a physiological cellular environment. J Biol Chem 2007;282:17289-96. (Pubitemid 47093237)
15. Nishishita N, Ijiri H, Takenaka C, Kobayashi K, Goto K, Kotani E, et al. The use of leukemia inhibitory factor immobilized on virus-derived polyhedra to support the proliferation of mouse embryonic and induced pluripotent stem cells. Biomaterials 2011;32:3555-63.
16. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. MCSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009;206:1089-102.
17. Noonan DM, Barbaro ADL, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 2008;27:31-40.
18. Holmes C, Stanford WL. Stem cell antigen-1: expression, function, and enigma. Stem Cells 2007;25:1339-47. (Pubitemid 47106000)
19. Toma JG, Akhavan M, Fernandes KJL, Barnabe-Heider F, Sadikot A, Kaplan DR, et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001;3:778-84. (Pubitemid 32842682)
20. Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer 2010;10:116-29.
21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schanper F. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem J 2003;374:1-20. (Pubitemid 37046923)
22. Rikhof B, de Jong S, Suurmeijer AJH, Meijer C, van der Graaf WTA. The insulin-like growth factor system and sarcomas. J Pathol 2008;217: 469-82.
23. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine & Growth Factor Rev 2005;16:107-37. (Pubitemid 40616111)
24. Kamura S, Matsumoto Y, Fukushi J, Fujiwara T, Iida K, Okada Y, et al. Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway. Br J Cancer 2010;103: 370-81.
25. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2003;23: 1439-47.
26. Karajannis MA, Vincent L, DiRenzo R, Shmelkov SV, Zhang F, Feldman EJ, et al. Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 2006;20:979-86. (Pubitemid 43797288)
27. Kwabi-Addo B, Ozen M, Ittmann M. The roles of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709-24. (Pubitemid 40065546)
28. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, et al. Disruption of the fibroblast growth factor-2 gene results in decrease bone mass and bone formation. J Clin Invest 2000;105:1085-93. (Pubitemid 30217693)
29. Marie PJ. Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 2003;316:23-32. (Pubitemid 37258340)
30. Ware CB, Horowitz MC, Renshaw BR, Hunt JS, Liggitt D, Koblar SA, et al. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 1995;121:1283-99.
31. Soube T, Naganawa T, Xiao L, Okada Y, Tanaka Y, Ito M, et al. Overexpression of fibroblast growth factor-2 causes defective bone mineralization and osteopenia in transgenic mice. J Cell Biochem 2005;95:83-94. (Pubitemid 41420218)
32. Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, Dorn GW, Lightfoot P, et al. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol Biol Cell 1995;6:1861-73.
33. Pitaru S, Kotev-Emeth S, Noff D, Kaffuler S, Savion N. Effect of basic fibroblast growth factor on the growth and differentiation of adult stromal bone marrow cells: Enhanced development of mineralized bone-like tissue in culture. J Bone Miner Res 1993;8:19-29.
34. Nagai H, Tsukuda R, Mayahara H. Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 1995;16:367-73.
35. Nakamura T, Harada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, et al. Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 1995;136:1276-84.
36. Hurley MM, Abreu C, Harrison JR, Lichtler AC, Raisz LG, Kream BE. Basic fibroblast growth factor inhibits Type I Collagen gene expression in osteoblastic MC-3T3-E1 cells. J Biol Chem 1993;268:5588-93. (Pubitemid 23090881)
37. Debiais F, Hott M, Graulet AM, Marie PJ. The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific. J Bone Mier Res 1998;13:645-55.
38. Canalis E, Centrella M, McCarthy T. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 1988;81:1572-7.
39. Malaval L, Aubin JE. Biphasic effects of leukemia inhibitory factor on osteoblastic differentiation. J Cell Biochem Suppl 2001;Suppl 36: 63-70.
40. Ge C, Xiao G, Jiang D, Franceschi RT. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol 2007;176: 709-18. (Pubitemid 46333984)
41. Schindeler A, Little DG. Ras-MAPK signaling in osteogenic differentiation: friend or foe? J Bone Miner Res 2006;21:1331-8. (Pubitemid 44300039)
42. Kawasaki T, Niki Y, Miyamoto T, Horiuchi K, Matsumoto M, Aizawa M, et al. The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation. Biomaterials 2010;31:1191-8.
43. Neto AHC, Queiroz KC, Milani R, Paredes-Gamero EJ, Justo GZ, Peppelenbosch MP, et al. Profiling the changes in signaling pathways in ascorbic acid/β-glycerophosphate-induced osteoblastic differentiation. J Cell Biochem 2011;112:71-7.
44. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45. (Pubitemid 27076454)
45. Yu PJ, Ferrari G, Galloway AC, Mignatti P, Pintucci G. Basic fibroblast growth factor (FGF-2): The high molecular weight forms come of age. J Cell Biochem 2007;100:1100-8. (Pubitemid 46480393)
46. Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma. Cancer Res 2000;60:6160-70.
47. Kim MS, Kim CJ, Jung HS, Seo MR, Juhnn YS, Shin HY, et al. Fibroblast growth factor 2 induces differentiation and apoptosis of Askin tumor cells. J Pathol 2004;202:103-12. (Pubitemid 38072851)
48. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007; 117:2766-77. (Pubitemid 47529608)
49. Haugsten EM, Wiedlocha A, Olsnes S, Wescha J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010; 8:1439-52.
50. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-37. (Pubitemid 32275592)